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Abstract 21 
Adipocyte-derived extracellular vesicles (EVs) may serve as novel endocrine mediators of adipose 22 
tissue and impact upon vascular health. However, it is unclear whether adipocyte-derived EVs are 23 
present in the human circulation. Therefore, the purpose of this study was to seek evidence for the 24 
presence of adipocyte-derived EVs in circulating plasma. Size exclusion chromatography of platelet-25 
free plasma identified fractions 5-10 as containing EVs by a peak in particle concentration, which 26 
corresponded with the presence of EV and adipocyte proteins. Pooling fractions 5-10 and subjecting 27 
to ultracentrifugation yielded a plasma EV sample, as verified by transmission electron microscopy 28 
(TEM) showing EV structures and Western blotting for EV (e.g. CD9 and Alix) and adipocyte 29 
markers. Magnetic beads and a solid phase assay were used to deplete the EV sample of the four 30 
major families of circulating EVs: platelet-, leukocyte-, endothelial- and erythrocyte-derived EVs. 31 
Post-depletion samples from both techniques contained EV structures as visualized by TEM, as well 32 
as CD9, Alix and classic adipocyte proteins. Post-depletion samples also contained a range of other 33 
adipocyte proteins from an adipokine array. Adipocyte proteins and adipokines are expressed in 34 
optimally processed plasma EV samples, suggesting that adipocyte-derived EVs are secreted into the 35 
human circulation.  36 
 37 
Précis 38 
Optimally isolated, human plasma-derived extracellular vesicles were found to contain multiple 39 
adipocyte markers, even after the depletion of major circulating extracellular vesicle populations.  40 
  41 
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Introduction 42 
The endocrine functions of adipose tissue have largely been attributed to adipokines; an array of 43 
soluble bioactive molecules secreted from adipocytes such as adiponectin and fatty acid binding 44 
protein (FABP)-41. Dysregulation of adipokine secretion is associated with obesity-related 45 
cardiovascular disease, insulin resistance, and type 2 diabetes2. Adiponectin, peroxisome proliferator-46 
activated receptor (PPAR)-γ, FABP4 and Perilipin have been detected within adipocyte-derived 47 
extracellular vesicles (EVs) in vitro3–12 indicating an additional method for endocrine signalling from 48 
adipose tissue. Dysfunctional adipocytes in obese adipose tissue may release an altered complement 49 
of EVs, which in addition to dysregulated adipokine secretion, help to promote the cardiovascular 50 
complications associated with obesity. Therefore, there is a need for comprehensive evidence for the 51 
existence of adipocyte-derived EVs in vivo to explore their potential as novel circulating biomarkers 52 
of adipocytes in vivo. 53 
EVs are heterogeneous submicron vesicles released from almost all cells in response to cellular stress, 54 
activation or apoptosis. EVs may originate from cytoplasmic multivesicular bodies which fuse with 55 
the plasma membrane to release vesicles typically <120 nm in diameter, often referred to as 56 
exosomes. EVs also include microvesicles, which are ~ 100-1000 nm in size and bud directly from 57 
the plasma membrane into the extracellular space. Both subclasses of EVs have a biomolecular 58 
composition similar to that of the original cell including specific lipids, proteins, and nucleic acids. 59 
Recent advances in methodology have enabled standardisation of nomenclature and characterisation 60 
of EV populations13.  61 
Most studies examining the release of EVs from adipocytes have been conducted in vitro using 3T3-62 
L1 cells3,6–9,11,12; a murine adipocyte cell line frequently used to model adipocyte functions. Others 63 
have also isolated EVs from human adipocytes and adipose tissue extracts4,5,10. These studies have 64 
demonstrated the functional relevance of adipocyte-derived EVs in the paracrine regulation of 65 
adipocyte metabolism14, monocyte to macrophage differentiation4 and regulation of hepatic insulin 66 
signaling5. Effects on vascular homeostasis have also been shown, including induction of 67 
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neovascularization and angiogenesis15,16, suggesting that adipocyte-derived EVs may influence 68 
vascular health within, and at sites remote to adipose tissue. However, evidence for the presence of 69 
adipocyte-derived EVs in the human circulation has not yet been confirmed, since EVs in blood are 70 
thought to derive primarily from platelets (with leukocyte-, endothelial- and erythrocyte-derived EVs 71 
contributing smaller populations17–19), and adipocytes lack a unique marker to readily distinguish them 72 
from other cells. Preliminary evidence from flow cytometric analyses showed that EVs contain the 73 
adipocyte markers FABP4 and adiponectin in human and mouse plasma18,20. However, the use of 74 
direct flow cytometry for EV measurements is sub-optimal as the lower limit of detection for many 75 
conventional flow cytometers is ~300 nm21, resulting in an incomplete assessment of the EV 76 
population. Separate studies have also shown that adiponectin, FABP4, Perilipin and PPAR-γ were 77 
associated with plasma EVs4,11,22 though in most cases, plasma samples were not processed in 78 
accordance with guidelines set out by the International Society for Extracellular Vesicles (ISEV)13. 79 
This may lead to false positive results from contamination of soluble adipokines present in the larger 80 
plasma protein pool. 81 
In light of these uncertainties, we utilized a combination of adipocyte markers and sample processing 82 
according to ISEV recommendations to seek evidence for the presence of adipocyte-derived EVs in 83 
healthy human plasma.  84 
  85 
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Materials and Methods 86 
Plasma EV isolation 87 
Ethical approval for this study was granted by Cardiff Metropolitan University School Research 88 
Ethics Committee and informed consent was obtained from each volunteer. Blood was drawn from 89 
seven healthy volunteers (3 males, 4 females) using a 19 G needle into 3.2% (w/v) sodium citrate 90 
vacutainers and immediately centrifuged (2500 x g, 15 minutes, 21°C) to isolate platelet-poor plasma 91 
(PPP). The first 3 mL of blood was discarded in line with recommended guidelines for collection of 92 
EVs from blood23,24. PPP was then pooled and centrifuged as above to isolate platelet-free plasma 93 
(PFP). PFP (1 mL) was then loaded onto Exo-spin™ midi size exclusion columns (Cell Guidance 94 
Systems, UK) and 30 x 500 µL fractions were collected. Fractions 5-10 were then pooled and 95 
ultracentrifuged (100,000 x g, 1 hour, 4°C) to pellet EVs (hereafter referred to as “pooled EVs”). 96 
 97 
Nanoparticle Tracking Analysis 98 
Quantification of EV populations was performed using nanoparticle tracking analysis (NTA) with a 99 
NanoSight LM10 instrument configured with a 488 nm laser and a sCMOS camera (Malvern 100 
Instruments Ltd, UK). A Harvard Apparatus syringe pump was utilized for EV measurements at a 101 
constant flow rate of 20 a.u. Camera shutter speed and gain were maintained at 607 and 15 102 
respectively. Sample videos were recorded for 60 seconds in repetitions of 5 using a capture screen 103 
gain of 8-11 and a camera level of 8-10. Samples were processed using a screen gain of 20 and a 104 
detection threshold of 4-6. Software version 3.1 (build 3.1.54) was used for capture and analysis. All 105 
experiments were performed in a temperature-controlled room at 22°C. Results are presented as 106 
particles/mL. 107 
  108 
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Western Blotting 109 
The protein concentration of individual column fractions (1-30) was determined using a NanoDrop 110 
1000 Spectrophotometer (ThermoFisher Scientific, UK). Samples (8 µg) of fractions 2-28, pooled 111 
EVs and post-depletion samples were prepared to 30 µL (neat or diluted with 1X PBS), boiled for 8 112 
minutes on a heat block, centrifuged (12,000 x g, 5 mins, 4°C) and kept on ice before loading onto 4-113 
12% Bis-Tris gels (ThermoFisher Sceintific). InstantBlue™ Protein Stain (Expedeon Ltd, UK) was 114 
used as a loading control. Amerhsam Hybond P 0.45 µm PVDF membranes (GE Healthcare, UK) 115 
were probed with the following antibodies (diluted 1:500 in either 5% (w/v) skimmed milk or 5% 116 
(w/v/) BSA both in tris-buffered saline with 0.05% (v/v) Tween 20): mouse monoclonal anti-Alix25, 117 
rabbit polyclonal anti-CD6326 (both purchased from Santa Cruz Biotechnology, USA); mouse 118 
monoclonal anti-CD8127 (purchased from Bio-Rad, UK); rabbit monoclonal anti-Adiponectin28 119 
(purchased from Abcam, UK); rabbit monoclonal anti-CD929, rabbit monoclonal anti-FABP430; rabbit 120 
monoclonal anti-Perilipin31 and rabbit monoclonal anti-PPARγ32 (purchased from Cell Signaling 121 
Technologies, USA). Proteins were analysed using reducing conditions with the exception of the 122 
tetraspanins (CD9, CD63 and CD81), which were analysed using non-reducing conditions. Signals 123 
were detected using either goat anti-mouse IgG-HRP33 or donkey anti-rabbit IgG-HRP34 diluted 124 
1:1000 in 5% (w/v) skimmed milk in tris-buffered saline with 0.05% (v/v) Tween 20) followed by 125 
Amersham ECL Western Blotting Detection Reagents (GE Healthcare). 126 
 127 
Transmission Electron Microscopy 128 
Pooled EVs were resuspended in 1X 0.22 µm-filtered PBS and then fixed with an equal volume of 4% 129 
(v/v) paraformaldehyde and kept at 4°C until processing for TEM the next day. Briefly, EVs (10 µL) 130 
were adsorbed onto glow discharged carbon formvar 200 mesh copper grids for 2 minutes. Grids were 131 
then blotted using filter paper, stained for 10 seconds with 2% (w/v) uranyl acetate before surplus 132 
stain was removed and grids were air-dried. Grids were imaged using a FEI Tecnai 12 TEM at 120 kV 133 
fitted with a Gatan OneView CMOS camera. 134 
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Sequential depletion of EV populations using magnetic beads 135 
Pooled EVs were diluted to a concentration of 1 x 1011 particles/mL using 1X 0.22 µm-filtered PBS in 136 
replicates of three. EVs were then incubated for 2 hours at room temperature with 3 µg/mL rabbit 137 
monoclonal anti-CD41 antibody35 (purchased from Abcam). Fifty µL (per sample) of pre-washed 138 
Dynabeads™ M-280 sheep anti-rabbit IgG magnetic beads (Life Technologies, UK) were added to 139 
EVs/anti-CD41 and incubated with mixing for 30 minutes at room temperature. Samples were then 140 
introduced into the magnet (DynaMag™-2, Life Technologies) to deplete CD41+ EVs: this was 141 
quantified using NTA. The process was repeated sequentially with 3 µg/mL rabbit monoclonal anti-142 
CD11b36, rabbit polyclonal anti-CD14437 and rabbit monoclonal anti-CD235a38 antibodies (all 143 
purchased from Abcam) to deplete CD11b+, CD144+ and CD235a+ EVs. Final supernatants were 144 
quantified using NTA and analysed by Western Blot with “pre-depletion” samples for the presence of 145 
adipocyte and EV markers. 146 
 147 
Solid-phase-based depletion of EV populations 148 
High binding ELISA plates (Greiner Bio-One Ltd, UK) were coated in triplicate with rabbit 149 
monoclonal anti-CD41, -CD11b, -CD144 or -CD235a antibodies (Abcam, as above) diluted to 3 150 
µg/mL in PBS overnight at 4°C. Pooled EVs were diluted to a concentration of 1 x 1011 particles/mL 151 
as above and incubated for 2 hours at room temperature in wells containing anti-CD41 antibody to 152 
deplete CD41+ EVs. Supernatants were then transferred to wells containing anti-CD11b antibody for 153 
2 hours at room temperature to deplete CD11b+ EVs. This process was then repeated sequentially 154 
with wells containing anti-CD144 antibody and anti-CD235a antibody to deplete CD144+ and 155 
CD235a+ EVs. Final supernatants were analysed as above. 156 
 157 
Time Resolved Fluorescence (TRF) 158 
8 
 
The efficiency of depletion of major circulating EV populations was assessed using time resolved 159 
fluorescence (TRF) as previously described39,40. Briefly, EVs were normalised to a concentration of 160 
1x1011 particles/mL in pre-depletion, post-CD41, post-CD11b, post-CD144 and post-CD235a samples 161 
from magnetic bead and solid phase-based depletion. EVs were then immobilised on high binding 162 
ELISA plates (Greiner Bio-One Ltd, UK) overnight at 4°C. EVs were blocked for 2 hours at room 163 
temperature using 1% (w/v) BSA before adding 3 µg/mL primary antibodies of interest (anti-CD41, 164 
anti-CD11b, anti-CD144 and anti-CD235a; as detailed above) in 0.1% (w/v) BSA overnight at 165 
4°C.Primary antibodies were detected using a biotin-labeled goat anti-rabbit IgG secondary antibody41 166 
(diluted 1:2500 in 0.1% BSA, purchased from Perkin Elmer, UK) for 1 hour at room temperature, 167 
followed by a streptavidin-europium conjugate (diluted 1:1000 in red assay buffer, both Perkin Elmer) 168 
for 45 minutes at room temperature. Time resolved fluorescence was measured on a BMG 169 
CLARIOstar® plate reader (BMG Labtech, UK). 170 
 171 
Detection of an array of adipokines in plasma EV samples 172 
A commercially available Proteome Profiler Human Adipokine Array Kit (R&D Systems, Bio-173 
Techne, UK) was used to analyse 58 adipocyte-related molecules in pre-depletion, post-magnetic 174 
bead depletion and post-solid phase depletion EV samples. Samples were diluted to load an absolute 175 
concentration of 2 x 1010 particles. The remainder of the experiment was performed according to the 176 
manufacturer’s protocol. Dot assays were detected using Amersham ECL Hyperfilm following 15- 177 
and 60-minute exposures. Blots were scanned and pixel densities analysed using HLImage++ 178 
(Western Vision Software, USA). A full list of analytes included in the kit is shown in Table S1. 179 
 180 
Statistical analysis 181 
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Data are presented as mean ± SEM. A one-way ANOVA with Tukey’s Multiple Comparison Test was 182 
used to analyse the difference between means. A p value of <0.05 was considered significant. Data 183 
were analysed using Graph Pad Prism (version 5; GraphPad Software Inc., CA). 184 
  185 
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Results 186 
Preparation of plasma-derived EVs using size exclusion chromatography 187 
Analysis of individual column fractions using Nanoparticle Tracking Analysis (NTA) showed a small 188 
peak in the concentration of particles/mL between fractions 5-10, followed by a large peak in particles 189 
and protein from fractions 12-26. Western blot analysis of fractions 2-28 showed the presence of both 190 
EV and adipocyte markers in fractions 6-10 but only adipocyte markers in fractions 11-28 (Figure 191 
S1). Plotting the ratio of particle concentration to protein concentration as described previously42 192 
showed fractions 5-10 to contain the highest number of particles:protein (Figure 1A). Therefore, these 193 
fractions were pooled and ultracentrifuged to pellet plasma-derived EVs. TEM of pelleted EVs 194 
indicated the presence of vesicle structures, and Western blot analysis showed the presence of 195 
classical EV and adipocyte markers in the pooled EVs of three different individuals (Figure 1B/C). 196 
Pooled EVs were shown to be deficient in the endoplasmic reticulum marker, Grp-94 (Figure S2A), in 197 
accordance with ISEV guidelines for expected proteins in EV isolates13. The supernatant of pelleted 198 
EVs following ultracentrifugation was deficient in CD9 (Figure S2B) indicating EVs were 199 
successfully pelleted by ultracentrifugation. 200 
 201 
Adipocyte markers remain following sequential depletion of major EV families 202 
Magnetic beads and a solid phase-based method were used to sequentially deplete EVs bearing 203 
markers of the four major EV populations in the circulating plasma of three different individuals. 204 
TEM analysis revealed EV structures to be present in both post-magnetic bead and post-solid phase 205 
depletion samples (Figure 2A). EV concentration was reduced by ~75% in both post-magnetic bead 206 
and post-solid phase depletion samples: 1.01 x 1011 ± 1.00 x 1010 particles/mL to 3.10 x 1010 ± 6.90 x 207 
109 particles/mL and 2.50 x 1010 ± 6.50 x 109 particles/mL respectively, p < 0.001, (n=5); Figure 2B. 208 
The detection of markers of the main EV populations in plasma (Platelet; CD41, monocytes; CD11b, 209 
endothelial cells; CD144 and erythrocytes; CD235a) were reduced in post-depletion samples 210 
following magnetic bead and solid-phase-based methods (Figure S3). Adiponectin, FABP4, PPARγ, 211 
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Perilipin, CD9 and Alix were reduced but still detectable in post-magnetic bead and post-solid phase 212 
depletion samples (Figure 2C). Interestingly, only the adipocyte specific PPARγ-2 isoform remained 213 
in post-depletion samples. 214 
 215 
Major adipokines are expressed in pre and post-depletion samples 216 
An adipokine array kit was used to probe for 58 adipokines (Table S1) in pre-depletion, post-magnetic 217 
bead and post-solid phase depletion plasma EV samples (Figure 3A). Major adipokines, including 218 
adiponectin, adipsin, leptin, preadipocyte factor (PREF)-1, resistin and visfatin, were detected in all 219 
samples (Figure 3B). No significant differences were observed between samples.  220 
  221 
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Discussion 222 
This study is the first of its kind to present a variety of evidence for the presence of adipocyte-derived 223 
EVs in the circulating plasma of healthy individuals. A panel of adipocyte markers and adipokines 224 
were detected in plasma EV samples after careful sample processing and depletion of EVs from major 225 
circulating sources. Adipocyte-derived EVs have proven to be important, novel endocrine mediators 226 
of adipocytes in vitro, thus their detection in the human circulation is an important step towards 227 
understanding their roles as mediators of adipocyte function, including potential effects on vascular 228 
health. 229 
Due to the complexity of plasma as a biofluid, platelet-depleted plasma was loaded onto size 230 
exclusion chromatography (SEC) columns. SEC has previously been shown to separate EVs quickly 231 
and effectively from the majority of non-vesicular protein in plasma39,43. Here, EVs were identified in 232 
fractions 5-10 from the high particle-to-protein ratio and the presence of EV markers, CD9, CD81 and 233 
Alix in these fractions (Figure 1 and Figure S1). Later fractions had a low particle-to-protein ratio and 234 
EV markers were not identified in these fractions. Additionally, the adipocyte markers adiponectin, 235 
FABP4, Perilipin and PPARγ were detected in fractions 5-10 but were also present in later fractions. 236 
Detection of these markers is in keeping with previous studies that have identified adipocyte markers 237 
within EVs from human plasma4,11,18,22. However, our data indicates that markers previously used to 238 
identify adipocyte-derived EVs in un-purified plasma samples are largely soluble and likely not 239 
associated with EVs as illustrated in Figure S1, where we show adiponectin, FABP4, Perilipin and 240 
PPARγ are all detected as soluble protein in SEC fractions not containing EVs, despite loading up to 241 
55x less volume. This finding has important implications for the measurement of adipocyte EV 242 
markers in human plasma, and highlights the importance of techniques such as SEC prior to analysis 243 
of adipocyte markers to avoid erroneous overestimations from soluble material. Pooling and 244 
subsequent ultracentrifugation of these fractions confirmed the presence of EV structures by TEM and 245 
both EV and adipocyte proteins by Western blotting (Figure 1, Figure S2A/B). We also observed the 246 
presence of adipokines in the supernatant of pelleted EVs highlighting the importance of the 247 
ultracentrifugation step after SEC. This is in keeping with previous studies, which have shown that 248 
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SEC is effective in removing ~95% of non-vesicular protein in a single step, but the EV-free 249 
supernatant is likely to contain residual, non-EV-associated plasma proteins, including adipokines39,43.  250 
The majority of plasma-derived EVs originate from cells that are in direct contact with blood, such as 251 
platelets, leukocytes, vascular endothelial cells and erythrocytes44. The location of adipocytes within 252 
adipose tissue may hinder the majority of adipocyte-derived EVs reaching the systemic circulation. 253 
Consequently, adipocyte-derived EVs are likely to form only a minor proportion of plasma-derived 254 
EVs. Furthermore, markers that uniquely identify adipocytes, such as adiponectin are readily secreted. 255 
High-speed centrifugation used for EV isolation may co-pellet these soluble markers with EVs, 256 
lending a false adipocyte character. We therefore applied two separate techniques to deplete the major 257 
circulating populations of plasma-derived EVs to establish whether adipocyte markers were reduced 258 
by depletion of “non-adipocyte” EVs and whether an adipocyte protein signature was retained post-259 
depletion. EV structures were visible by TEM following sequential depletion of major plasma EV 260 
populations (Figure 2A) though the overall concentration of EVs detected by NTA was reduced by 261 
around 75% (Figure 2B). Both techniques were shown to reduce the expression of each marker used 262 
for depletion, with the magnetic bead based approach depleting these markers beyond detection by 263 
time resolved fluorescence (Figure S3). This suggests both techniques are effective in reducing the 264 
populations of major circulating EVs in plasma. Expression of adiponectin, FABP4 and PPARγ was 265 
reduced post-depletion (Figure 2C), suggesting a proportion of these markers are in some way 266 
associated with EVs from non-adipocyte populations. Although their expression is predominantly 267 
associated with adipocytes, both FABP4 and PPARγ have previously been shown to be produced by 268 
other cells including macrophages45,46 perhaps explaining the partial loss in signal post-depletion. 269 
FABP4 was not detected in all samples (possibly due to individual variations in donors) and was often 270 
detected at a higher molecular weight than expected. FABP4 has previously been reported to form 271 
homodimers, particularly upon ligand activation47 though the absence of expression in some samples 272 
reaffirms the need to use multiple markers when analysing adipocyte-derived EVs. However, whilst 273 
both isoforms of PPARγ were detected in pre-depletion samples, only PPARγ2 remained in post-274 
depletion samples. PPARγ2 is an adipocyte-specific nuclear transcription factor48 and its presence in 275 
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combination with adiponectin, FABP4 and Perilipin in post-depletion samples is highly indicative of 276 
adipocyte origin. Furthermore, a number of major adipokines were detected in post-depletion samples 277 
using an adipokine array kit, including the angiogenic factors leptin and resistin, and adipokines 278 
adipsin, PREF-1, and visfatin (Figure 3). This further evidences the presence of adipocyte markers in 279 
EV samples that have been depleted of major circulating plasma EV populations. The EV markers 280 
Alix and CD9 were reduced but still present in post-depletion samples (Figure 2C). This tallies with a 281 
reduced concentration of EVs but also indicates that EVs are still present in post-depletion samples, 282 
supporting the TEM data. Taken together, our data show that after depleting EVs from major sources 283 
in plasma using either magnetic beads or solid phase depletion, adipocyte and EV markers are still 284 
detectable, supporting the presence of adipocyte-derived EVs. It is important to note that we observed 285 
differences in expression patterns of both EV and adipocyte markers between individuals, however, 286 
this is most likely due to natural biological variation within our small group of donors. 287 
In conclusion, this study is the first of its kind to provide evidence for the presence of adipocyte-288 
derived EVs in circulating plasma using multiple adipocyte and EV markers, and conducted in 289 
accordance with international recommendations. Our data also emphasize the need for careful EV 290 
preparation when analysing adipocyte markers to avoid contribution of signal from soluble adipocyte 291 
material. Whilst adipocyte-derived EVs may only constitute a relatively small fraction of the total EV 292 
population in circulating plasma, this may not necessarily reflect a minor effect on vascular health 293 
since the content of the EVs is likely to dictate their function, particularly in EVs derived from 294 
dysfunctional adipocytes. Our data thus provide a platform for future investigations into circulating 295 
adipocyte-derived EVs as potential novel biomarkers of adipocytes in health and obesity-driven 296 
cardiovascular disease. 297 
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Figure 1: Detailed analysis of pooled plasma EVs. (A) Fractions 5-10 showed the highest ratio of 416 
particles-to-protein and the presence of EV structures by TEM (B, red arrows indicate EV structures) 417 
following ultracentrifugation. (C) Pooled EVs from three different individuals (labelled 1, 2, and 3) 418 
were analysed by Western blot for EV markers: CD9, CD63, CD81 and Alix, and adipocyte markers: 419 
Adiponectin, FABP4, PPARγ and Perilipin (n=3). Solid red boxes indicate the predicted molecular 420 
weight for each antigen; the dotted red box may indicate a FABP4 dimer ~32 kDa. 421 
Figure 2: Adipocyte and EV markers were maintained post-magnetic bead and solid phase 422 
depletion. (A) EV structures were visible by TEM in post-magnetic bead depletion (left, scale bar 200 423 
nm) and post-solid phase depletion (right, scale bar 1000 nm). (B) EV concentration was reduced 424 
following sequential depletion of major EV families using magnetic beads or a solid phase method, 425 
***p = 0.005 (n=5). (C) Adiponectin, FABP4, PPARγ-2, Perilipin, CD9 and Alix were still present in 426 
post-depletion samples of three different individuals. 427 
Figure 3: Major adipokines were present in post-magnetic bead and –solid phase depletion 428 
samples. (A) Inverted raw data of dot blots pre-depletion, post-magnetic beads and post-solid phase 429 
depletion. Major adipokines are highlighted with corresponding pixel densities (B). Representative 430 
dot blots of n=3.  431 
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Supplemental data 439 
Figure S1: Co-elution of EV and adipocyte markers from human plasma. Plasma (1 mL) was 440 
loaded onto SEC columns and 30 x 500 µL fractions were collected. The concentration of 441 
particles/mL was measured using NTA and the protein concentration was measured using Nanodrop 442 
for each fraction. Fractions 2 – 28 were then analysed by Western blot (8 µg/lane) for the EV 443 
markers; CD9, CD81 and Alix, and the adipocyte markers; Adiponectin, FABP4, Perilipin and 444 
PPARγ. A small peak in particle concentration in fractions 5-10 corresponds with the detection of EV 445 
and adipocyte markers. A larger peak in particles and protein in fractions 12-26 corresponds with 446 
adipocyte markers only (n=3).  447 
Figure S2: Confirmation of an EV population. (A) Western blot analysis of 3T3-L1 cell (positive 448 
control to confirm antibody specificity) and pooled plasma EV lysates for the endoplasmic reticulum 449 
protein, Grp-94 (MW~100 kDa). (B) Western blot analysis of pooled plasma EVs and the 450 
corresponding supernatant from the EV pellet following ultracentrifugation for the EV marker, CD9 451 
(MW~ 22kDa). 452 
Figure S3: The efficiency of magnetic bead and solid phase depletion. Equal numbers of EVs were 453 
immobilised onto ELISA plates pre- and post-CD41, -CD11b, -CD144 and -CD235a depletion using 454 
magnetic beads (A) and solid phase (B). Pre and post samples were then analysed by time resolved 455 
fluorescence for the presence of the depleted marker and plotted as a percentage of the “Pre” sample 456 
fluorescence. ND = not detected. 457 
Table S1: Adipokine array appendix. A list of the 58 analytes included in adipokine array kit with 458 
mean pixel density values ± SEM for pre-depletion, post-magnetic bead depletion and post-solid 459 
phase depletion samples (n=3). 460 
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Supplementary Figure 2 465 
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Supplementary Figure 3 468 
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Supplementary Table 1 471 
Adipokine Pre-depletion Post-beads Post-solid phase 
Adiponectin 24,425 ± 3,808 17,417 ± 4,531 24, 429 ± 8,412 
Angiopoietin-1 5,978 ± 2,030 4,961 ± 1,892 5,465 ± 2,071 
Angiopoietin-2 9,963 ± 2,596 8,095 ± 2,270 7,482 ± 2,509 
Angiopoietin-like 2 7,484 ± 1,997 6,260 ± 2,090 5,543 ± 2,023 
Angiopoietin-like 3 2,153 ± 908 2,582 ± 1,075 1,772 ± 721 
CD257 (B cell  
activating factor) 
3,182 ± 1,165 3,212 ± 1,280 2,584 ± 933 
Bone morphogenetic  
protein (BMP)-4 
3,403 ± 1,269 3,267 ± 1,392 3,565 ± 1,212 
Cathepsin D 8,320 ± 2,891 7,734 ± 3,011 11,028 ± 5,763 
Cathepsin L 3,310 ± 1,690 9,065 ± 3,214 2,661 ± 1,404 
Cathepsin S 13,899 ± 4,093 13,172 ± 4,106 11,031 ± 4,783 
Chemerin 2,000 ± 983 2,405 ± 1,119 1,964 ± 790 
Complement Factor D 
(Adipsin) 
2,578 ± 1,173 4,494 ± 2,262 2,254 ± 851 
C-Reactive  
Protein (CRP) 
8,585 ± 3,518 6,317 ± 1,873 8,281 ± 3,709 
Dipeptidyl  
peptidase (DPP)-4 
9,591 ± 3,337 11,138 ± 3,757 10,306 ± 4,681 
Endocan 7,882 ± 2,761 9,140 ± 3,097 7,221 ± 2,227 
EN-RAGE 3,846 ± 1,619 4,634 ± 1,763 3,033 ± 1,110 
Fetuin B 2,620 ± 964 3,060 ± 1,265 2,104 ± 659 
Fibroblast Growth  
Factor (FGF)-2 
2,407 ± 921 2,355 ± 1,156 1,624 ± 426 
FGF-19 6,987 ± 2,361 5,403 ± 2,117 7,197 ± 2,920 
Fibrinogen 35,002 ± 4,995 38,828 ± 2,134 36,146 ± 5,145 
Growth Hormone 2,314 ± 571 3,279 ± 738 2,149 ± 62 
Hepatocyte growth  
factor (HGF) 
1,932 ± 382 2,340 ± 402 1,210 ± 604 
Intercellular adhesion 
 molecule (ICAM)-1 
11,422 ± 5,785 8,230 ± 1,496 7,768 ± 1,746 
Insulin growth factor binding 
protein (IGFBP)-2 
3,047 ± 290 2,243 ± 881 1,313 ± 603 
IGFBP-3 4,233 ± 1,710 3,945 ± 1,320 3,489 ± 1,225 
29 
 
IGFBP-4 7,911 ± 2,475 8,848 ± 3,219 6,903 ± 2,286 
IGFBP-6 5,850 ± 2,075 7,141 ± 2,633 5,144 ± 1,663 
IGFBP-7 1,206 ± 185 1,451 ± 20 527 ± 398 
Interleukin (IL)-1β 2,921 ± 930 3,149 ± 1,269 2,447 ± 891 
IL-6 3,234 ± 1,039 3,238 ± 1,417 2,919 ± 1,260 
IL-8 7,350 ± 2,172 7,811 ± 2,729 8,001 ± 3,149 
IL-10 8,716 ± 3,176 8,237 ± 3,133 10,025 ± 3,603 
IL-11 1,928 ± 892 2,622 ± 1,351 1,779 ± 823 
Transforming growth 
 factor (TGF)-β1 
1,687 ± 282 2,024 ± 327 1,601 ± 34 
Leptin 1,902 ± 978 1,596 ± 832 1,135 ± 567 
Leukaemia inhibitory 
 factor (LIF) 
2,310 ± 1,056 2,055 ± 906 1,704 ± 748 
Lipocalin-2 26,197 ± 2,855 24,184 ± 7,044 24,200 ± 8,432 
Monocyte chemoattractant 
protein (MCP)-1 
2,640 ± 676 2,864 ± 1,047 2,464 ± 430 
Macrophage colony 
stimulating factor (M-CSF) 
2,847 ± 1,034 3,270 ± 1,435 2,161 ± 709 
Macrophage migration 
inhibitory factor (MIF) 
4,646 ± 1,785 12,566 ± 2,293 4,130 ± 1,121 
Myeloperoxidase 2,035 ± 641 2,378 ± 1,054 1,727 ± 503 
Nidogen-1 4,820 ± 1,340 7,034 ± 2,488 4,173 ± 1,853 
Oncostatin M 4,984 ± 1,743 3,647 ± 1,555 4,961 ± 2,042 
Pappalysin-1 8,222 ± 2,764 5,699 ± 2,099 8,715 ± 3,445 
Pentraxin-3 3,903 ± 1,809 3,639 ± 1,703 3,401 ± 1,608 
Preadipocyte  
factor (PREF)-1 
3,525 ± 1,393 3,237 ± 1,378 2,325 ± 943 
Proprotein  
convertase 9 
1,953 ± 937 1,904 ± 969 1,423 ± 706 
RAGE 3,676 ± 663 3,041 ± 1,251 3,194 ± 1,202 
CCL5 26495 ± 6,371 15,406 ± 4,790 25,518 ± 8,363 
Resistin 4,121 ± 2,436 4,731 ± 2,062 4,024 ± 1,348 
Serpin A8 1,712 ± 639 1,979 ± 826 1,437 ± 499 
Serpin A12 2,215 ± 128 1,997 ± 990 1,327 ± 329 
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Plasminogen activator  
inhibitor (PAI)-1 
5,613 ± 1,623 4,858 ± 1,909 4,560 ± 1,853 
Tissue inhibitor of 
metalloproteinase (TIMP)-1 
4,024 ± 1,006 24,028 ± 4,264 3,550 ± 1,231 
TIMP-3 1,932 ± 390 1,015 ± 352 1,557 ± 690 
Tumor necrosis 
 factor (TNF)-α 
4,260 ± 1,574 5,900 ± 2,245 4,942 ± 1,872 
Vascular endothelial  
growth factor (VEGF) 
2,338 ± 160 2,669 ± 1,105 1,555 ± 716 
Visfatin 4,029 ± 1,842 3,820 ± 1,715 3,540 ± 1,285 
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